Loading
A phase 3 trial of Pemetrexed, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Immutep S.A.S., active and no longer recruiting.
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) is a phase 3 interventional study registered as NCT06726265 by Immutep S.A.S., with 756 participants planned, started 2025-03-21 and due to reach its primary completion in 2027-06. Interventions recorded: eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed, pembrolizumab (KEYTRUDA®), Placebo. Conditions listed: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.